Board of Directors

John Moore is a seasoned executive with extensive leadership experience across
multiple industries. He currently serves on the boards of two private and three public companies. In the life sciences sector, he is Chairman of Scientific Industries (SCND-OTCQB), a manufacturer of laboratory instruments, and Trialogics, a clinical trial informatics company. He also serves as a director of Phase Holographic Imaging, a provider of live cell imaging systems for life science researchers. Phase Holographic is publicly traded on both the Swedish Spotlight Market and the OTCQB in the U.S. John is also a shareholder and director of Cormetech, a global leader in air pollution control solutions for power plants.

Previously, he was CEO of Acorn Energy (2006–2015), where he led the acquisition of CoaLogix for $11 million and its later sale for $101 million. He also oversaw the public listing of Comverge through Citibank and exited through a secondary offering led by Goldman Sachs at a $600 million valuation prior to its sale to Constellation Energy. Earlier, in 2002, he served as Partner and CEO of Edson Moore Healthcare Ventures, managing the $148 million acquisition of 16 drug delivery investments from Elan Pharmaceuticals.

John holds a degree from Rutgers University and brings deep strategic insight to his board roles.

Christopher Cox is a Co-Founder and a General Partner of Population Health Partners, L.P., a global healthcare focused investment firm, since April 2020. Chris serves on the boards of Scientific Industries (SCND-OTXQB), a manufacturer of laboratory instruments; Niroda Therapeutics, a private biopharmaceutical company focused on the development and commercialization of non-opioid therapeutics for acute and chronic pain; and Civia Health, a private clinical trial site management organization.

Previously, from January 2012, Chris was a partner, Chairman of the Corporate Department, and a member of the management committee of Cadwalader, Wickersham & Taft LLP, a global law firm. From February 2016 to March 2019, Chris served as Executive Vice President and Chief Corporate Development Officer of The Medicines Company, a global biopharmaceutical company, where he was responsible for business development and strategy.

Marcus Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), the US$85 billion sovereign wealth fund for the State of Alaska. Marcus manages the investment team at APFC and leads all investment decisions related to APFC’s investment portfolio within the guidelines established by APFC’s Board of Trustees.

Before joining the APFC in 2012, Marcus held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to private equity investing at PCG Capital Partners (2005- 2010), and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012).

Rüdiger Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 19 years he has led more than 80 transactions for the health care division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before joining Merck KGaA, Rüdiger spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen. Rüdiger also served 5 years on the Supervisory Board of Cytotools AG, Freiburg, Germany.

Dr Dixon brings to the Board extensive entrepreneurial and technical experience in founding, building and running listed and unlisted technology-based companies.

In 2011, Dr Dixon co-founded Cynata Inc, now a subsidiary of ASX-listed Cynata Therapeutics Ltd (ASX:CYP), a stem cell and regenerative medicine company progressing with its Cymerus stem cell therapy now progressing through Phase II studies.

In 2014, Ian co-founded Cardio Therapeutics Pty Ltd and managed the PCSK9 cardiovascular discovery program until the company was acquired by Nyrada Inc in advance of the IPO of Nyrada in 2019.

In 2018, the genetic medicines company founded by Ian listed as Exopharm Ltd (ASX:EX1) and Ian was a co-inventor of a number of inventions, including granted US patents, in the exosome field.

Ian has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.

Gisela is an international business leader with significant experience developing and launching new pharmaceutical products and delivering successful corporate strategies in highly competitive global markets. She is currently the CEO and Managing Director of Noxopharm Ltd (ASX:NOX).

Gisela has held senior positions with Amgen, Bayer, Siemens Medical Solutions and Merck/MSD generating successful commercial and scientific outcomes. She has strong global pharmaceutical industry networks and served as President, Vice President and Treasurer of the Australian Pharmaceutical Physicians Association (APPA; now MAPA) for many years with serving until recently as Past-President. She is also the Australian delegate for the International Federation of Associations of Pharmaceutical Physicians (IFAPP), which connects the pharmaceutical industry globally. She is a Graduate of the Australian Institute of Company Directors (GAICD).

Gisela holds various Board roles, as Executive Director of Noxopharm, and Nonexecutive Director of Nyrada Inc. and a not-for-profit sports organization. Recently, she was appointed as Chair of the Biotechnology Committee of BIO NSW, a Not-for-Profit body to promote Life Sciences across NSW and to serve on a Policy Taskforce of AusBiotech Ltd.